Managing Partner, Qiming Venture Partners

Council (Honorary)——Nisa LEUNG

Nisa Leung is Managing Partner of Qiming Venture Partners, leading its health care investments. Qiming Venture Partners is a leading investment firm in China with over 480 portfolio companies.

She currently sits on the board of Zai Lab (NASDAQ:ZLAB; HKSE:9688), CanSino Biologics (SSE:688185; HKSE:6185), Caidya, Chain Medical Labs, Belief BioMed, Zencore Biologics, Valgen MedTech, Alamar Biosciences among others. Her other investments include Gan & Lee (SSE:603087), Venus MedTech (HKSE:2500), New Horizon Health (HKSE:6606), Berry Genomics (SZSE:000710), Broncus (HKSE:2216), CITIC Pharma (acquired by Shanghai Pharmaceutical HKSE: 2607), Crown Bioscience (acquired by JSR Life Sciences), Aeonmed Medical, Novast Pharmaceuticals, Nurotron, Origene Technologies (acquired by VCAN Bio SSE:600645), Richen, Vision Pro, MEDx, Cure Genetics, Goodwill (SSE:688246), SinoCellTech (SSE:688520), Sino Biological (SZSE:301047), Apollomics (NASDAQ:APLM), SinoUnited Health, Schrödinger (NASDAQ:SDGR) , Recursion (NASDAQ:RXRX), Insilico Medicine, Structure Therapeutics (NASDAQ:GPCR), Jacobio (HKSE:1167), Hope Medicine, Sinotau, PlusLife among others.

Prior to joining Qiming, she was co-founder of Biomedic Holdings with operations and investments in medical devices, pharmaceuticals and health care services in China including Novamed Pharmaceuticals (acquired by SciClone NASDAQ:SCLN) and U-Systems (acquired by GE Healthcare). Nisa was Venture Partner of PacRim Ventures in Menlo Park, and was previously with Softbank/Mobius Venture Capital.

Nisa has been recognized by the Forbes Global 100 VC Midas List in 2019, 2020, 2021 and 2022 and named Best Women VCs List by Forbes China (#1 in 2022, #2 in 2021) and Most Powerful Women in Business by Fortune China in 2022.

Nisa earned her MBA from Stanford Graduate School of Business and a BS from Cornell University. She is currently visiting lecturer at Harvard Law School, member of Stanford Graduate School of Business Advisory Council and serves as an Independent Non-executive Director of the Hong Kong Exchanges and Clearing Limited (“HKEX”), Board Member of Hong Kong Palace Museum, Council Member of China Pharmaceutical Innovation and Research Development Association (PhIRDA) and Founding Member and Chair of Pharmaceutical Innovation Investment Specialty Committee of PhIRDA.